drugset / Trial / NCT01364181

The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01364181

NaSingle-groupOpen-labelTreatment

Summary

Pulmonary hypertension (PH) is a serious complication of COPD which is associated with shorter survival, more frequent exacerbation, and increased use of health resources. There is no effective pharmacological treatment for COPD-associated PH. Therefore, the investigators wanted to evaluate the effect of udenafil, a phosphodiesterase- 5 (PDE-5) inhibitor, on exercise capacity of severe COPD patients.

Timeline

Start
2010-03
Primary completion
2011-03
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Udenafil Small molecule 50 mg Oral